Treatment Information

Back

Melanoma treatment details. Chemotherapy.

Institute Gustave Roussy, Paris, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Paris
Treatments:ChemotherapyHospital:Institute Gustave Roussy
Drugs:Journal:Link
Date:Jun 2013

Description:

Patients:
This phase 2 study involved BRAF-mutant metastatic melanoma patients who were divided into two separate treatment groups. Group A consisted of 45 patients with a median age of 57 years and 49% male. Group B had 46 patients with a median age of 52 years and 61% male.

Treatment:
Patients in group A were treated with the chemotherapy agent dacarbazine and the biologic therapy agent selumetinib, a small molecule inhibitor of MAPK/ERK kinases that interferes with cancer cell growth.
Patients in group B were treated with dacarbazine and a placebo.

Toxicities:
The most severe toxicities in group A were of grade 4 and included grade 3-4 neutropenia and diarrhea. Visual disturbances, acne, and peripheral edema (swelling) were also reported.

The most severe toxicities in group B were of grade 4 and included grade 3-4 fatigue, thrombocytopenia, and neutropenia. Nausea, diarrhea, vomiting, and constipation were also reported.

Results:
The median overall survival for groups A and B was 13.9 and 10.5 months, respectively.

Support:
This study was supported by AstraZeneca.

Correspondence: Dr. Caroline Robert; email: [email protected]



Back